Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Tf Holdings LLC currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units. This indicates that the company's current patent applications are being reviewed by different specialized groups, likely reflecting diverse technical aspects of their biotechnological innovations.
AGGARWAL, SAHIL CHANDER is the busiest examiner for the company, with 1 pending office action. This examiner handles a portion of the company's 2 pending office actions. The other pending matter is overseen by the second distinct examiner in the second distinct art unit. This split prosecution means that the company must manage separate examination tracks simultaneously.
With 2 distinct examiners and 2 distinct art units involved, the company's prosecution risk is diversified. Any specific challenges encountered with AGGARWAL, SAHIL CHANDER will only affect a portion of the current pending inventory. This structure requires the company's legal team to be prepared for potentially different examination styles and timelines across the two active matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §102 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
| WARD, PAUL V | 1 | 83.2% | -12.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18228881 | WOUND TREATMENT TOPICAL COMPOSITION CONTAINING CANNABINOIDS | WARD, PAUL V | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18388057 | TOPICAL COMPOSITION CONTAINING CANNABINOIDS | AGGARWAL, SAHIL CHANDER | 1623 | §103 | Final Rejection | — | Pending | Nov 08, 2023 |
| 18228881 | WOUND TREATMENT TOPICAL COMPOSITION CONTAINING CANNABINOIDS | WARD, PAUL V | 1622 | §102 | Non-Final OA | — | Pending | Aug 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTf Holdings LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Sahil Chander Aggarwal has the most, with 1 of Tf Holdings LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
